Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Trial Profile

Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs LY 03005 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 21 Dec 2018 New source identified and integrated (ClinicalTrials.gov NCT03785652).
    • 02 Feb 2018 New trial record
    • 23 Jan 2018 According to a Luye Pharma Group media release, primary endpoint (Reduction in 17- item Hamilton Rating Scale) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top